日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib

在接受维莫非尼治疗的晚期黑色素瘤患者中,新出现的非典型黑色素细胞病变中存在NRAS Q61R和BRAF G466A突变

Parekh, Vishwas; Sobanko, Joseph; Miller, Christopher J; Karakousis, Giorgos; Xu, Wei; Letrero, Richard; Elenitsas, Rosalie; Xu, Xiaowei; Elder, David E; Amaravadi, Ravi; Schuchter, Lynn M; Nathanson, Katherine L; Wilson, Melissa A; Chu, Emily Y

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib

卡铂、紫杉醇和索拉非尼治疗黑色素瘤患者的体细胞突变与临床结果的相关性

Wilson, Melissa A; Zhao, Fengmin; Letrero, Richard; D'Andrea, Kurt; Rimm, David L; Kirkwood, John M; Kluger, Harriet M; Lee, Sandra J; Schuchter, Lynn M; Flaherty, Keith T; Nathanson, Katherine L

Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)

对接受 BRAF 抑制剂达拉非尼 (GSK2118436) 治疗的转移性黑色素瘤患者进行肿瘤基因分析

Nathanson, Katherine L; Martin, Anne-Marie; Wubbenhorst, Bradley; Greshock, Joel; Letrero, Richard; D'Andrea, Kurt; O'Day, Steven; Infante, Jeffrey R; Falchook, Gerald S; Arkenau, Hendrik-Tobias; Millward, Michael; Brown, Michael P; Pavlick, Anna; Davies, Michael A; Ma, Bo; Gagnon, Robert; Curtis, Martin; Lebowitz, Peter F; Kefford, Richard; Long, Georgina V

The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma

FBXO4肿瘤抑制因子可作为BRAFV600E依赖性转移性黑色素瘤的屏障。

Lee, Eric K; Lian, Zhaorui; D'Andrea, Kurt; Letrero, Richard; Sheng, WeiQi; Liu, Shujing; Diehl, J Nathaniel; Pytel, Dariusz; Barbash, Olena; Schuchter, Lynn; Amaravaradi, Ravi; Xu, Xiaowei; Herlyn, Meenhard; Nathanson, Katherine L; Diehl, J Alan

A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility

DMRT1 内的第二个独立位点与睾丸生殖细胞肿瘤易感性相关

Kanetsky, Peter A; Mitra, Nandita; Vardhanabhuti, Saran; Vaughn, David J; Li, Mingyao; Ciosek, Stephanie L; Letrero, Richard; D'Andrea, Kurt; Vaddi, Madhavi; Doody, David R; Weaver, Joellen; Chen, Chu; Starr, Jacqueline R; Håkonarson, Håkon; Rader, Daniel J; Godwin, Andrew K; Reilly, Muredach P; Schwartz, Stephen M; Nathanson, Katherine L

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

通过共同靶向 MEK 和 IGF-1R/PI3K 可以克服黑色素瘤中由 RAF 激酶开关介导的对 BRAF 抑制剂的获得性耐药性

Jessie Villanueva, Adina Vultur, John T Lee, Rajasekharan Somasundaram, Mizuho Fukunaga-Kalabis, Angela K Cipolla, Bradley Wubbenhorst, Xiaowei Xu, Phyllis A Gimotty, Damien Kee, Ademi E Santiago-Walker, Richard Letrero, Kurt D'Andrea, Anitha Pushparajan, James E Hayden, Kimberly Dahlman Brown, Sylv

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

CRAF抑制剂可诱导携带非V600E BRAF突变的黑色素瘤细胞凋亡

Smalley, K S M; Xiao, M; Villanueva, J; Nguyen, T K; Flaherty, K T; Letrero, R; Van Belle, P; Elder, D E; Wang, Y; Nathanson, K L; Herlyn, M

The Y deletion gr/gr and susceptibility to testicular germ cell tumor

Y染色体缺失gr/gr与睾丸生殖细胞肿瘤的易感性

Nathanson, Katherine L; Kanetsky, Peter A; Hawes, Rachel; Vaughn, David J; Letrero, Richard; Tucker, Kathy; Friedlander, Michael; Phillips, Kelly-Anne; Hogg, David; Jewett, Michael A S; Lohynska, Radka; Daugaard, Gedske; Richard, Stéphane; Chompret, Agnés; Bonaïti-Pellié, Catherine; Heidenreich, Axel; Olah, Edith; Geczi, Lajos; Bodrogi, Istvan; Ormiston, Wilma J; Daly, Peter A; Oosterhuis, J Wolter; Gillis, Ad J M; Looijenga, Leendert H J; Guilford, Parry; Fosså, Sophie D; Heimdal, Ketil; Tjulandin, Sergei A; Liubchenko, Ludmila; Stoll, Hans; Weber, Walter; Rudd, Matthew; Huddart, Robert; Crockford, Gillian P; Forman, David; Oliver, D Timothy; Einhorn, Lawrence; Weber, Barbara L; Kramer, Joan; McMaster, Mary; Greene, Mark H; Pike, Malcolm; Cortessis, Victoria; Chen, Chu; Schwartz, Stephen M; Bishop, D Timothy; Easton, Douglas F; Stratton, Michael R; Rapley, Elizabeth A